1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement

Sponsor
Novartis Pharmaceuticals
Study ID
NCT02756650
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Canakinumab — DRUG
    150 mg or 300 mg of canakinumab was administered monthly. IV (SC after month 6)

Study Details

Primary objective of the study was to evaluate the safety and efficacy of canakinumab on the clinical and inflammatory findings of Behced Disease patients with neurologic and vascular involvement.

Key Dates

Start date
Jun 23, 2016
Status verified
May 2020
Primary completion
Jan 31, 2019
Completion
Jan 31, 2019

Study Design

Enrollment
8 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Canakinumab
    Canakinumab was administered monthly

Primary Outcome Measure

Number of Participants With Attacks [ Time Frame: 30 days ]

Related Studies